Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Medtronic is a medical devices business based in the US. Medtronic stocks (MDT.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $79.37 – a decrease of 1.96% over the previous week. Medtronic employs 95,000 staff and has a trailing 12-month revenue of around $30.8 billion.
Finder Award
Interactive Brokers
National Bank Direct Brokerage
| Latest market close | $79.64 |
|---|---|
| 52-week range | $75.10 - $111.55 |
| 50-day moving average | $82.01 |
| 200-day moving average | $84.95 |
| Wall St. target price | $92.09 |
| PE ratio | 25.7871 |
| Dividend yield | $2.67 (3.42%) |
| Earnings per share (TTM) | $3.10 |
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of $79.64 from 2023-03-27
| 1 week (2023-03-21) | -1.96% |
|---|---|
| 1 month (2023-02-28) | -3.82% |
| 3 months (2022-12-28) | 4.38% |
| 6 months (2022-09-28) | -3.57% |
| 1 year (2022-03-25) | -26.57% |
|---|---|
| 2 years (2021-03-26) | -32.83% |
| 3 years (2020-03-27) | 89.89 |
| 5 years (2018-03-28) | 1.50% |
Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $30.8 billion |
|---|---|
| Operating margin TTM | 19.26% |
| Gross profit TTM | $21.7 billion |
| Return on assets TTM | 3.99% |
| Return on equity TTM | 7.84% |
| Profit margin | 13.21% |
| Book value | $38.67 |
| Market capitalisation | $106.4 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 26.86
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 01/01/2019) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 4.07/100
Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.28/100
Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9/100
Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.
Dividend payout ratio: 51.81% of net profits
Recently Medtronic has paid out, on average, around 51.81% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.42% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 3.42% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.67 per share.
Medtronic's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Medtronic's most recent dividend payout was on 14 April 2023. The latest dividend was paid out to all shareholders who bought their shares by 23 March 2023 (the "ex-dividend date").
Medtronic's shares were split on a 2:1 basis on 27 September 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.
Over the last 12 months, Medtronic's shares have ranged in value from as little as $75.1019 up to $111.547. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.7208. This would suggest that Medtronic's shares are less volatile than average (for this exchange).
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies.
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
The best stock trading app for beginners is easy to use and offers free trades.
Read more…
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…Everything we know about the Neuraxis IPO plus information on how to buy in.
Everything we know about the Brera IPO plus information on how to buy in.
Everything we know about the TXO Energy IPO plus information on how to buy in.
Your guide to how ETFs work and whether this type of investment is right for you.
Steps to owning and managing TXG stock, with 24-hour and historical pricing before you buy.
The best stock trading app for beginners is easy to use and offers free trades.
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
An healthcare company, NFT tech developer and baby products retailer are among the IPOs expected to take place this month.
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
The best time to buy stocks could be right after an IPO, during expansion periods or when other investors are buying or selling.
